AKR1C3 has recently been identified as a potential therapeutic target in both CRPC and ER-positive breast cancer, since it can promote intratumoral steroidogenesis to provide the hormones required for nuclear receptor activation and tumor progression (4, 6, 8–11). Here, AKR1C3 is linked to neoplasm.